Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | LY3164530 |
Synonyms | |
Therapy Description |
LY3164530 is a bispecific antibody that targets EGFR and c-Met and inhibits activation of downstream signaling, resulting in decreased proliferation of EGFR and c-Met overexpressing tumor cells, but LY3164530 has significant toxicities (PMID: 29926131). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
LY3164530 | LY-3164530|LY 3164530 | EGFR Antibody 55 MET Antibody 28 | LY3164530 is a bispecific antibody that targets EGFR and c-Met and inhibits activation of downstream signaling, resulting in decreased proliferation of EGFR and c-Met overexpressing tumor cells, but LY3164530 has significant toxicities (PMID: 29926131). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02221882 | Phase I | LY3164530 | A Study of LY3164530 in Participants With Cancer | Completed | USA | 0 |